FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
FREEDOM-M was a randomized, double-blind, placebo-controlled trial of patients with PAH, a chronic, life-threatening illness. The study enrolled 349 patients who were not receiving any approved PAH medication, with the population for the primary analysis consisting of the 228 patients who had access to the 0.25 mg tablet at randomization. These patients were administered oral treprostinil or placebo twice daily, with the doses titrated to effect over the course of the 12-week trial. The majority of patients were in
The primary efficacy endpoint of the trial was the change in 6MWD at 12 weeks for the 228 patients. Preliminary analysis of the FREEDOM-M results demonstrates that those patients receiving oral treprostinil improved their median 6MWD by approximately 23 meters (p=0.0125, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial’s pre-specified statistical analysis plan) as compared to patients receiving placebo. The median change from baseline was 25 meters for oral treprostinil and -5 meters for placebo at week 12.
The combined 6MWD and Borg Dyspnea Score rating (shortness of breath test) was significantly improved (p=0.0497). Preliminary analysis of other secondary efficacy measures, including change in Borg Dyspnea Score rating, trough walk at Week 11, change in Dyspnea Fatigue Index, change in WHO functional class, time to clinical worsening (as defined by death, transplant, atrial septostomy, hospitalization due to PAH or at least a 20% decrease in six-minute walk and initiation of another approved PAH therapy), and PAH signs and symptoms did not differ significantly between oral treprostinil and placebo (p>0.05).
An analysis of all 349 FREEDOM-M patients demonstrates that those patients receiving oral treprostinil improved their median 6MWD by approximately 25.5 meters (p=0.0001, Hodges-Lehmann estimate and non-parametric analysis of covariance) as compared to patients receiving placebo.
Adverse events seen in the trial included headache, nausea, diarrhea, and flushing, which are common in patients receiving prostanoid therapy. Detailed analysis of adverse events is ongoing. All patients in the trial had the option to continue receiving oral treprostinil in an open-label continuation study after completion of the 12-week period. Of the 287 patients who were eligible to enroll, approximately 279 patients entered the open-label continuation study. Of these, approximately 183 patients are currently being treated with oral treprostinil, with the longest duration of treatment exceeding three years.
“This is my dream come true,” said
“These results build upon the treprostinil franchise we have established with Remodulin and Tyvaso. We are excited that the primary efficacy analysis of this trial confirms the benefits of oral treprostinil on 6MWD, as the delivery of treprostinil via a twice daily oral tablet, if it secures regulatory approval, would provide a critically important additional treatment option for patients with this severe disease,” said
The 313-patient FREEDOM-C(2) trial is studying oral treprostinil in PAH patients who are receiving an endothelin receptor antagonist and/or a PDE-5 inhibitor. Preliminary analysis of the results of the trial are expected to be announced in
Further review and analysis of the FREEDOM-M preliminary results are ongoing. A summary of the preliminary analysis conducted thus far can be accessed via United Therapeutics’ website at http://ir.unither.com/events.cfm beginning at
Conference Call
On
The conference call is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the conference call will be available for two weeks and can be accessed by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291, and using conference code: 72976350.
This conference call is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.
About Tyvaso (treprostinil) Inhalation Solution
Indication
Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (
The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.
While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.
Important Safety Information
-- TYVASO is intended for oral inhalation only. TYVASO is approved for use
only with the TYVASO Inhalation System.
-- The safety and efficacy of TYVASO have not been established in patients
with significant underlying lung disease (such as asthma or chronic
obstructive pulmonary disease) and in patients under 18 years of age.
Patients with acute pulmonary infections should be carefully monitored
to detect any worsening of lung disease and loss of drug effect.
-- TYVASO may increase the risk of bleeding, particularly in patients
receiving anticoagulants.
-- In patients with low systemic arterial pressure, TYVASO may cause
symptomatic hypotension. The concomitant use of TYVASO with diuretics,
antihypertensives, or other vasodilators may increase the risk of
symptomatic hypotension.
-- Hepatic or renal insufficiency may increase exposure to TYVASO and
decrease tolerability. TYVASO dosage adjustments may be necessary if
inhibitors of CYP2C8 such as gemfibrozil or inducers such as rifampin
are added or withdrawn.
-- The most common adverse events seen with TYVASO in greater than or equal
to 4% of PAH patients and more than 3% greater than placebo in the
placebo-controlled clinical study were cough (54% vs 29%), headache (41%
vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea
(19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%).
-- TYVASO should be used in pregnancy only if clearly needed. Caution
should be exercised when TYVASO is administered to nursing women.
For more information about TYVASO, please see the Full Prescribing Information, Patient Package Insert, and the TYVASO Inhalation System Instructions for Use manual at www.Tyvaso.com or call 877-
About Remodulin (treprostinil) Injection
Indication
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (
In patients with PAH requiring transition from Flolan® (epoprostenol sodium), Remodulin is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.
Important Safety Information
-- Chronic intravenous infusions of Remodulin are delivered using an
indwelling central venous catheter. This route is associated with the
risk of blood stream infections (BSI) and sepsis, which may be fatal.
Therefore, continuous subcutaneous infusion is the preferred mode of
administration.
-- Remodulin should be used only by clinicians experienced in the diagnosis
and treatment of PAH. Remodulin is a potent pulmonary and systemic
vasodilator. It lowers blood pressure, which may be further lowered by
other drugs that also reduce blood pressure. Remodulin inhibits platelet
aggregation and therefore, may increase the risk of bleeding,
particularly in patients on anticoagulants. Remodulin dosage adjustment
may be necessary if inhibitors or inducers of CYP2C8 are added or
withdrawn.
-- Initiation of Remodulin must be performed in a setting with adequate
personnel and equipment for physiological monitoring and emergency care.
Therapy with Remodulin may be used for prolonged periods, and the
patient’s ability to administer Remodulin and care for an infusion
system should be carefully considered.
-- Remodulin dosage should be increased for lack of improvement in, or
worsening of, symptoms and it should be decreased for excessive
pharmacologic effects or for unacceptable infusion site symptoms.
-- Abrupt withdrawal or sudden large reductions in dosage of Remodulin may
result in worsening of PAH symptoms and should be avoided. Caution
should be used in patients with hepatic or renal insufficiency.
-- The most common side effects of Remodulin included those related to the
method of infusion. For subcutaneous infusion, infusion site pain and
infusion site reaction (redness and swelling) occurred in the majority
of patients. These symptoms were often severe and could lead to
treatment with narcotics or discontinuation of Remodulin. For
intravenous infusion, line infections, sepsis, arm swelling, tingling
sensations, bruising, and pain were most common. General side effects
(>5% more than placebo) were diarrhea, jaw pain, vasodilatation, and
edema.
For more information about Remodulin, please see the Full Prescribing Information atwww.Remodulin.com or call 877-
About
Forward-looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations regarding our pursuit and potential success in obtaining regulatory approvals for oral treprostinil, including our filing for regulatory approval in 2012, the future commercial availability of oral treprostinil to patients, that preliminary analysis of the results of the FREEDOM-C(2) trial will be announced in
REMODULIN and TYVASO are registered trademarks of
SOURCE